Research programme: targeted cancer therapeutics - Intrexon/ZIOPHARM

Drug Profile

Research programme: targeted cancer therapeutics - Intrexon/ZIOPHARM

Alternative Names: ACT-based immunotherapy - Intrexon/ZIOPHARM; Adoptive cell transfer-based immunotherapy - Intrexon/ZIOPHARM; Anti-CD3-anti-EGFR CLM - Intrexon/ZIOPHARM; CAR-T cell therapeutics - Intrexon/ZIOPHARM/Merck Serono; Cell linking moieties - Intrexon/ZIOPHARM; Cetux-CAR T cells - Intrexon/ZIOPHARM; CLM expressing allogeneic cell therapeutics - Intrexon/ZIOPHARM; ERC-RTS-CLM; Nimo-CAR T cells - Intrexon/ZIOPHARM; Non-viral adoptive cellular cancer immunotherapies - Intrexon/ZIOPHARM; pRTS-IFNα; RTS-IFNα

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer Intrexon Corporation; Merck Serono; University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class Bispecific antibodies; CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene expression modulators; Gene transference; Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer
  • Research Cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Jan 2017 Intrexon establishes CRADA with National Cancer Institute for the development of targeted cancer therapeutics in Solid tumours
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2015 ZIOPHARM Oncology plans clinical study for Leukaemia and Solid tumours in USA (ZIOPHARM Oncology 10-K, February 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top